PI3King on MYCN to improve neuroblastoma therapeutics
- PMID: 22340587
- DOI: 10.1016/j.ccr.2012.01.018
PI3King on MYCN to improve neuroblastoma therapeutics
Abstract
MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN.
Copyright © 2012 Elsevier Inc. All rights reserved.
Comment on
-
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.Sci Transl Med. 2012 Jan 4;4(115):115ra3. doi: 10.1126/scitranslmed.3002977. Sci Transl Med. 2012. PMID: 22218692 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
